Haleon (HLN): What the Fundamentals Show in the Medicine Cabinet

Haleon (HLN) is the largest listed company in the world built solely around everyday consumer health, and that single-mindedness is what makes a Haleon stock analysis different from looking at a diversified pharmaceutical or household goods group. There is no drug pipeline to model, no detergent division to carry a weak quarter. What the organisation owns instead is a shelf: toothpaste for sensitive teeth, painkillers, multivitamins, decongestants, indigestion remedies. Demand for those products is steady, the brands are old, and the economics turn on pricing power, gross margin and how efficiently the company converts profit into cash. This article walks through what Haleon actually does, what its most recent reported figures show, and which variables are likely to move the numbers next.

What Haleon Actually Sells

Haleon was created in July 2022, when GSK (GSK) demerged its consumer healthcare arm, a business that had itself been assembled as a joint venture with Pfizer (PFE). Both former parents have since gone: GSK sold its remaining holding in 2024, and Pfizer disposed of its final 7.3% stake in 2025. Haleon now trades as an independent FTSE 100 company with no legacy shareholder overhang, listed in London with an American depositary share line in New York.

The portfolio is organised around a handful of categories. Oral Health is the largest and includes Sensodyne, parodontax and Polident. Vitamins, Minerals and Supplements (VMS) is led by Centrum and Emergen-C. Pain Relief covers Panadol, Advil and Voltaren. Respiratory Health holds Otrivin and Theraflu, and there is a Digestive Health and therapeutic skin health grouping alongside. The products are sold in more than 170 markets, overwhelmingly through supermarkets, pharmacies and increasingly e-commerce, which means Haleon negotiates with a concentrated set of very large retailers.

Two features of this model matter for anyone reading the accounts. First, most of these are self-pay, low-ticket purchases, so volumes are far less cyclical than in discretionary consumer categories, but they are not immune to shoppers trading down to supermarket own-label. Second, one category is genuinely seasonal: cold and flu demand depends on how severe a winter respiratory season turns out to be, and a mild season can knock a full percentage point or more off group growth without anything being wrong with the business.

Haleon Stock Analysis: What the Latest Reported Numbers Show

Haleon reports on a UK calendar, publishing half-year and full-year results in sterling, with quarterly trading statements in between. The two most recent substantive reports are the full year to 31 December 2025, published in February 2026, and the half year to 30 June 2026, published on 30 July 2026.

For FY2025, reported revenue was £11,030m, down 1.8% against £11,233m in 2024. That decline is a currency and disposal effect rather than a trading one: on an organic basis revenue grew 3.0%. Management described that 3% as below its own medium-term expectation, attributing the shortfall largely to a weak cold and flu season and subdued consumer confidence in North America. Adjusted operating profit for the year was £2,526m, an adjusted operating margin of 22.9%, up 60 basis points on 2024 and up 160 basis points on an organic basis. Adjusted diluted earnings per share rose 5.0% to 18.8p, from 17.9p the year before.

The H1 2026 numbers show the same pattern with a slightly better top line. Revenue for the six months was £5,602m, up 2.2% reported and 2.6% organic. The composition of that organic growth is worth pausing on: 2.1 percentage points came from price and only 0.5 points from volume and mix. Within the half there was a clear sequential improvement, with organic growth accelerating from 2.2% in the first quarter to 3.1% in the second, and second-quarter volume and mix contributing 1.4 points. Haleon also reported that 73% of the portfolio gained or maintained market share.

By category, Oral Health was the standout in the first half, with revenue of £1.8bn, up 6.4% reported and 7.3% organic, helped by launches including Sensodyne Clinical Repair and parodontax Gum Strengthen and Protect. Respiratory Health was the drag, with a strong allergy performance more than offset by a double-digit decline in cold and flu products. North America, the region that disappointed in 2025, grew 3.1% organically in the half with positive volume, which management linked to shelf resets, innovation and e-commerce momentum.

Margins, Cash and the Balance Sheet

The clearest trend in the recent reporting is margin. Adjusted gross margin in H1 2026 was 66.5%, an expansion of 140 basis points, and adjusted operating margin reached 24.3%, up 120 basis points. Adjusted operating profit grew 8.2% at constant currency and adjusted diluted EPS grew 12.0%, both well ahead of the 2.6% organic revenue growth underneath them. In plain terms, Haleon is currently generating most of its earnings growth from productivity and mix rather than from selling materially more units. Note that the half-year margin is not directly comparable to the full-year figure, because the seasonal profile means the second half typically carries a different cost and revenue mix; the 22.9% FY2025 margin and the 24.3% H1 2026 margin are separate measures.

Cash generation has been solid. FY2025 free cash flow was £1.9bn. In H1 2026, net cash from operating activities was £1,044m and free cash flow was £769m. Net debt stood at £7,513m at 30 June 2026, equivalent to 2.5 times net debt to adjusted EBITDA, against 2.6 times at the end of 2025 after the group returned £1.1bn to shareholders during that year. Haleon's stated medium-term target is leverage of around 2.5 times, so the balance sheet is currently sitting on that target rather than being deleveraged aggressively or stretched.

That leverage level is a deliberate choice and a structural feature of the story. A business with predictable cash flows can carry more debt than a cyclical one, but it does mean interest costs are a permanent line item and that the room for large acquisitions is limited without either issuing equity or pausing buybacks. Management has framed its capital allocation priorities as investing for growth, executing value-accretive bolt-on acquisitions, and returning excess cash, all underpinned by a commitment to a strong investment grade balance sheet.

The Dividend and the Buyback

Haleon's shareholder return policy has two parts. On dividends, the Board proposed a total 2025 dividend of 7.1p per ordinary share, of which 4.9p was the final, representing a payout ratio of roughly 38% of 2025 adjusted earnings. The stated policy is to grow the ordinary dividend at least in line with adjusted earnings, subject to market conditions and Board approval. For the first half of 2026 the interim dividend was set at 2.4p per ordinary share, up 9% on the prior-year interim.

On buybacks, Haleon announced a £500m programme for 2026 alongside its full-year results, and by the half-year stage had completed £457m of it. Buybacks at this scale reduce the share count and mechanically support earnings per share growth, which is part of why adjusted diluted EPS grew 12.0% in H1 2026 while adjusted operating profit grew 8.2% at constant currency.

A payout ratio in the high thirties is a long way from the stretched distributions seen at some other UK income names. It leaves headroom for the dividend to grow faster than earnings for a period if the Board chose, but it also signals that Haleon is not positioning itself primarily as a high-yield stock. Investors comparing it with Reckitt Benckiser (RKT) or Unilever (ULVR) on income grounds should look at payout policy and cover, not just the headline yield. The same caution applies when setting it against Procter and Gamble (PG), whose category mix is different again.

Any Haleon stock analysis has to handle the pence-versus-pounds trap carefully, because London quotes are in pence. Haleon shares closed at 337.30p on 8 September 2026, which is £3.373 per share, and the stock has traded in a 52-week range of roughly 274.40p to 419.50p. That price sits toward the lower half of the range.

On that closing price, the shares trade on approximately 17.9 times the FY2025 adjusted diluted EPS of 18.8p, and the FY2025 total dividend of 7.1p equates to a trailing yield of about 2.1%. A price-to-earnings multiple simply expresses how many years of current earnings the market is paying for; for a business with slow but reliable organic growth, the level of that multiple usually reflects how durable investors think the brands and the margin expansion are, rather than any expectation of rapid growth. The trailing figures also lag the business, since they use full-year 2025 earnings while 2026 first-half EPS grew at a double-digit rate.

Where the Risks Sit

Several things could reasonably change the picture:

The mix of price and volume. With 2.1 of the 2.6 points of H1 2026 organic growth coming from price, Haleon needs volumes to keep recovering. Pricing that runs ahead of what shoppers accept is what pushes them toward own-label alternatives, particularly in VMS and pain relief where retailer brands are well established.
Respiratory seasonality. A run of mild winters would keep pressure on a category that already declined at a double-digit rate in the first half of 2026, and that pressure lands on group growth regardless of how well Oral Health performs.
Currency. Haleon reports in sterling but earns a large share of revenue in dollars, euros and emerging-market currencies, which is why FY2025 reported revenue fell 1.8% while organic revenue rose 3.0%. Reported figures can diverge meaningfully from underlying trading in either direction.
Leverage. Net debt of £7,513m at 2.5 times adjusted EBITDA is manageable but permanent, and it constrains how much can be spent on acquisitions without trading off buybacks.
Regulation and litigation. This is a standing feature of any organisation selling medicines and supplements at global scale across many jurisdictions.

What to Watch From Here

Haleon has reaffirmed FY2026 guidance of 3% to 5% organic revenue growth and high single-digit adjusted operating profit growth at constant currency. The first half came in at 2.6% organic, so reaching the guided range depends on the second-half acceleration continuing beyond the 3.1% achieved in the second quarter.

Three specific things are worth tracking in the next set of reports. The first is the volume and mix component of organic growth, because that is the cleanest read on whether the brands are winning shoppers rather than simply raising prices. The second is whether gross margin can keep expanding once the current round of supply chain and productivity work is lapped, since margin has been doing most of the work in the earnings line. The third is North America, where a return to consistent volume growth would remove the specific weakness management flagged for 2025.

Beyond those, the balance between buybacks, dividends and bolt-on acquisitions will show how management intends to use the cash once leverage is settled at around 2.5 times. Haleon is a business with a narrow, well-understood job: sell familiar self-care brands, defend shelf space, widen margins and convert profit into cash. The evidence in the current numbers is that it is doing the margin and cash parts well while the volume part is still recovering. Whether that balance shifts is the question the next few reporting periods will answer.